THOUSAND OAKS, Calif., Nov. 14, 2013 /PRNewswire via COMTEX/ — Amgen (AMGN) will host a webcast investor meeting at the American Heart Association (AHA) Scientific Sessions 2013 on Tuesday, Nov. 19, at 7 p.m. CST. Sean E. Harper, M.D., executive vice president of Research and Development at Amgen, along with members of Amgen’s clinical development team and clinical investigators, will participate at the investor meeting to discuss data being presented at AHA.Continue reading
Author Archive: AZBio
AZ Biotech in the spotlight at Governor’s Celebration of Innovation
The Arizona biotech community stepped into the spotlight at the 2013 Governor’s Celebration of Innovation Awards. Continue reading
Opportunity Alert: Faculty Research Scientist at St. Joe’s
The Heart and Lung Institute at St. Joseph’s Hospital and Medical Center is seeking an Faculty Research Scientist to join their team.Continue reading
Washington Update – November 2013
As a member of the Council of State Bioscience Associations, AZBio is pleased to share the following Washington Update for our AZBio Members.Continue reading
1,200th Worldwide Implant of the SynCardia Total Artificial Heart Occurs in Indiana
Patrick O’Hara Also is the 1st Indianan to be Implanted with the SynCardia Heart and the 1st Discharged From the Hospital Without a Human Heart, Thanks to the Freedom® Portable DriverContinue reading
SGB and Yulex Partner to Double Guayule Rubber Yield Through an Accelerated Breeding Platform
SAN DIEGO, CA and PHOENIX, AZ–(Marketwired – Nov 12, 2013) – SGB Inc., an agricultural biotechnology company, and Yulex Corporation, a biomaterial company, announced today a collaboration to establish a genomics and molecular breeding platform focused on accelerating the crop improvement of Guayule as a sustainable source of biorubber that can replace traditional tropical or petroleum-based rubber for medical, consumer and industrial markets.Continue reading
Saluting Our AZBio Veterans
This Veteran’s Day, join us in saluting our AZBio Veterans. Continue reading
TGen-led study reveals TWEAK-Fn14 as key drug target
Next steps: Drug development and clinical trials that could benefit patientsContinue reading
W.L.Gore receives new FDA Approval and CE Mark on two innovative technologies
Its been a banner week for the medical division of W.L. Gore & Associates. The Flagstaff-based medical device company announced FDA approval of its GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface on November 6, 2013 followed by the announcement of receiving a CE mark for its the GORE EXCLUDER Iliac Branch Endoprosthesis on November 7, 2013. Continue reading